# Tmunity Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tmunity-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.tmunity.com
- Total disclosed funding: $135M
- Latest round: Series B (Oct 22, 2019)
- Investors on record: 11

## About

Tmunity Therapeutics Inc. is a biotechnology company focused on developing innovative cell and gene therapies to address significant healthcare challenges, particularly in oncology and autoimmune diseases.Tmunity Therapeutics Inc. specializes in cell and gene therapy. Founded in 2015, the company is headquartered in Philadelphia, US. The founders include Arie Belldegrun and Bruce Levine. Tmunity has successfully completed 5 deals, with its most recent funding round, Series B, occurring on December 20, 2022, where they raised USD 75.00 mn, led by Andreessen Horowitz. The total amount raised by the company amounts to USD 75.00 mn, with a current valuation of USD 369.585 mn.Tmunity is primarily focused on advancing the field of cell and gene therapy, offering innovative products and services designed to address critical healthcare challenges. The company's core offerings include proprietary platforms for T cell engineering, aimed at developing personalized therapies for various types of cancers and autoimmune diseases. By harnessing the power of the immune system, Tmunity's solutions enhance patient outcomes and expand treatment options. Targeted towards healthcare providers and research institutions, the company serves a client base that includes hospitals, academic medical centers, and biotechnology firms across North America and Europe. Their products are tailored to meet the needs of oncologists and immunotherapy specialists, aiming to deliver treatments that address unmet medical needs in both adult and pediatric populations.Tmunity generates revenue through strategic partnerships and collaborative agreements with biotechnology and pharmaceutical companies. These transactions often involve joint development agreements, allowing Tmunity and its partners to advance specific therapeutic candidates. Additionally, the company offers customized services related to its T cell engineering platforms. Revenue is derived from milestone payments linked to the progress of clinical trials and royalties from future product sales, positioning Tmunity as a key player in the cell and gene therapy landscape.Tmunity's strategy for future growth includes the development of new products that leverage their T cell engineering technology, targeting the launch of several innovative therapies within the next few years. The company aims to expand into new markets, particularly Europe and Asia, by 2025. Recent funding from the Series B round will be utilized to support these initiatives, enhancing their research and development capabilities. In December 2022, Tmunity was acquired by Kite Pharma, Inc., which may further influence their strategic direction and product offerings.

## Funding rounds

- Series B, Oct 22, 2019, $75M — Andreessen Horowitz, Gilead Sciences, Inc., University of Pennsylvania Pension Fund, Be The Match BioTherapies, Westlake Village BioPartners, BrightEdge Ventures
- Series A, Feb 6, 2018, $50M — Kleiner Perkins, Lilly Asia Ventures, Gilead Sciences, Inc., Ping An Trust, University of Pennsylvania Pension Fund, Be The Match BioTherapies, Parker Institute for Cancer Immunotherapy
- Seed, Jan 12, 2016, $10M — Lilly Asia Ventures, Penn Medicine

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Seed, Series A
- Penn Medicine — Seed
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A
- Gilead Sciences, Inc. — Series A, Series B
- Ping An Trust — Series A
- University of Pennsylvania Pension Fund — Series A, Series B
- Be The Match BioTherapies — Series A, Series B
- Parker Institute for Cancer Immunotherapy — Series A
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series B
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series B
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Series B